3rd Anti-Infectives Partnering & Deal-Making Summit

Venue: The San Diego Marriott La Jolla

Location: La Jolla, california, United States

Event Date/Time: Jan 26, 2006 End Date/Time: Jan 27, 2006
Registration Date: Jan 26, 2006
Early Registration Date: Dec 26, 2005
Abstract Submission Date: Dec 26, 2005
Report as Spam

Description

7:00 Registration & Breakfast
7:45 Chairperson's Opening Remarks

Session I: Recent Deals in Infectious Diseases
8:00 Building on Successes: Merck's Approach to Anti-infective Partnering

Sundeep Lal, Ph.D., MBA, Senior Director, External Scientific Affairs, Merck & Co.

8:30 TBD
Gilead
9:00 It’s Not About the Target
David Pompliano, Vice President, Biology, MMPD CEDD, GlaxoSmithKline
9:30 Refreshment Break
10:00 PANEL: Recent Partnering and Interest in Antibiotics
Chair: Dennis Molnar, Executive Director, Corporate Development, Paratek Pharmaceuticals
Praveen Tipirneni, Senior Director, Corporate Development, Cubist Pharmaceuticals
Sundeep Lal, Ph.D., MBA, Senior Director, External Scientific Affairs, Merck & Co.
Yujiro Hata, VP Business Development, Enanta Pharmaceuticals

Session II: Antibiotics/Antifungals
10:45 Review of Global Antibiotic/Antifungal Pipelines
Praveen Tipirneni, Senior Director, Corporate Development, Cubist Pharmaceuticals
11:15 Anti-Infective Biologics: A 'Humaneered' Anti-Pseudomonas Antibody

Mark Alfenito, President, KaloBios Pharmaceuticals
11:45 The Commercialization Story of Factive and Oscient - The Sequel
Glenn Tillotson, VP, Scientific & Medical Relations, Oscient Pharmaceuticals
12:15 Pipeline Building in an Era of Market Segmentation Driven by Drug Resistance
Kevin Eastwood, Senior Vice President, Business Development, Achillion Pharmaceuticals
12:45 Lunch
1:45 PANEL: Investment Opportunities in the Anti-Infectives Space
Chair: Jeff Stein, Partner, San Diego, Sofinnova Ventures
Doug Wall, Partner, Venture Advisors
John North, President & CEO, Inimex
Eckard Weber, M.D., Venture Partner, Domain Associates
Camille Samuels, Managing Director, Versant Ventures
Jeanne Cunicelli, Partner, Bay City Capital

SESSION III: Valuation and Business Models
2:45 Valuation of Compounds: What does it mean- comparing Anti-Infectives
Michael McCully, Director, Recombinant Capital
3:15 The European Biotech Model – Consolidation or Disappointment?
Ursula Theuretzbacher, Center for Anti-Infective Agents, Europe
3:45 Refreshment Break

SESSION IV: IP and Regulatory
4:15 Developing Pricing & Reimbursement Strategies for Antiinfectives
Volker Janssen, Partner, Simon-Kucher & Partners
4:45 Opportunities to Partner w/ the Division of Microbiology & Infectious Diseases Resources
Katherine Taylor, Therapeutics Development Program Officer, NIAID, NIH
5:15 Update on Patent Law and Its Impact on Life Sciences Inventions
Lisa Haile, Ph.D., J.D., Partner, DLA Piper
5:45 Networking Reception/Poster Viewing




Day 2: Friday, January 27, 2006

7:15 Registration & Breakfast
8:00 KEYNOTE ADDRESS
From a Biotech to a Biopharmaceutical Company: The Replidyne Story
Ken Collins, President & CEO, Replydine, Inc.

SESSION V: AntiVirals
8:45 Where are the future areas of growth in infectious diseases, 2006?
John Lebbos, M.D., Infectious Diseases Director, Decision Resources, Inc.

9:15 Development of HCV Anti-Viral Therapies: A Partnering Perspective from InterMune
Tom Kassberg, SVP, Business Development & Corporate Strategy, InterMune Pharmaceuticals
9:45 Refreshment Break
10:15 Trends in Prophylactic Vaccines
Clement Lewin, Vice President US Govt. Affairs & Strategy, Acambis
10:45 NexBio: Leading the Quest for the Ultimate Influenza Medicine
Mang Yu, President & CEO, NexBio, Inc.
11:15 PANEL: Bird Flu Pandemic
Mang Yu, President & CEO, NexBio, Inc.
Invited: Mark Armitage, Chiron Vaccines
Invited: Michel Baijot, GSK
Invited: Jonathan Klein-Evans, MedImmune
12:00 Lunch

SESSION VI: Diagnostics & Drug Discovery Approaches
1:00 Molecular Diagnostics meet Therapeutics
Henrik Stender, VP, Research and Development, AdvanDx
1:20 Building Partnering Value through Targeted Antibiotic Discovery and Development
Graham Johnson, Chief Research Officer, Rib-X Pharmaceuticals
1:40 Targeted Anti-Infectives for Treatment of Drug Resistant Infections
Elizabeth Posillico, President & CEO, Elusys Therapeutics, Inc.
2:10 Tarmogens: Immunotherapy using Recombinant Saccharomyces Cerivisiae for the Treatment of Chronic Viral Diseases
David Apelian, M.D., Ph.D., MBA, Chief Medical Officer, GlobeImmune
2:30 Broad-Spectrum Antiviral Drugs: Why not?
Paul Olivo, President & CSO, Apath, LLC
2:50 Refreshment Break
3:10 "It's a Jungle Out There": Successful Discovery of New Anti-Infectives from Plants
Victoria Gordon, CEO, EcoBiotics
3:30 The Evolving Vaccine Industry, and the Business of Biodefense
Elaine Cheung, Sr Mgr Business Development, VaxGen
3:50 Preventing Expression of Chromosomal Resistance Determinates
J. Kevin Judice, PhD, CSO, Achaogen, Inc

4:10 Oral Presentations from Selected Abstracts
Submit your abstract before Dec. 26, 2005 to be considered
4:30 Conference Concludes
Sponsorships & Exhibition Opportunities Available
Call 626-256-6405 for More Details

Venue

4240 La Jolla Village Drive
La Jolla
california
United States
MORE INFO ON THIS VENUE

Additional Information

To Submit an Abstract visit www.gtcbio.com. A few abstracts will be selected for oral presentation.

Types